Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Meds Catalog

Levothyroxine Sodium

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Tablet Multiple FDA sponsors Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
Apr 22, 2026, 10:07 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:07 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: April 15, 2026

Updated: April 15, 2026, 10:04 AM UTC

Sources:
Image coming soon
Levothyroxine Sodium

Levothyroxine Sodium

Drug type: Generic ingredient • Generic profile • No FDA branded products linked

Both Tablet Rx required 100% storefront ready

Species: Both

Manufacturer: Multiple FDA sponsors

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Levothyroxine Sodium

For replacement therapy for diminished thyroid function in dogs. Species commonly shown: Both, Dog, No Use Class Stated Or Implied.

Generic name
Levothyroxine Sodium
Brand names
Thyro-Tabs® Canine, ThyroKare™
Manufacturer
Multiple FDA sponsors
Species
Both, Dog, No Use Class Stated Or Implied
Dosage forms
Tablet
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Thyro-Tabs® Canine ThyroKare™
Dosage forms
Tablet

Indications / Uses

For replacement therapy for diminished thyroid function in dogs.

Warnings / Contraindications

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Overdose, Vomiting, Diarrhoea, Lethargy (see also Central nervous system depression in 'Neurological'), Panting, Lack of efficacy - NOS.

FAQ

Both, Dog, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Tablet

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For replacement therapy for diminished thyroid function in dogs.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • For oral use in dogs only
  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)
  • Decreased percentage of reticulocytes (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • For oral use in dogs only
  • wobbly/unsteady walking
  • Loss of appetite
  • Decreased percentage of reticulocytes

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)
  • Decreased percentage of reticulocytes (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA sponsors
Form: Tablet
Identifiers:
NADA: 141448 NADA: 141539 NDC Package: 11695-6957-1 NDC Package: 11695-6957-2 NDC Package: 11695-6958-1 NDC Package: 11695-6958-2 NDC Package: 11695-6959-1 NDC Package: 11695-6959-2 NDC Package: 11695-6960-1 NDC Package: 11695-6960-2 NDC Package: 11695-6961-1 NDC Package: 11695-6961-2 NDC Package: 11695-6962-1 NDC Package: 11695-6962-2 NDC Package: 11695-6963-1 NDC Package: 11695-6963-2 NDC Package: 11695-6964-1 NDC Package: 11695-6964-2 NDC Package: 11695-6965-1 NDC Package: 11695-6965-2
Source metadata:

Warnings / Contraindications

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
20
Species represented
2
Grouped by Body System
Digestive (2) · Loss of appetite, Decreased appetite Skin & allergy (1) · Hair loss Neurologic (1) · Unsteady walking (ataxia) Other (28) · Decreased urine concentration, Decreased percentage of reticulocytes, Decreased mean corpuscular volume
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Cat 1
Digestive 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (26) Cat (6)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Cat Serious - 1
Digestive Dog Serious - 1
Skin & allergy Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Digestive Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

2

FOI

2

ThyroKare™

SPL · SPL

Open original
FDA Structured Product Label

ThyroKare™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Neogen Corp.
NADA
141-539
Status
RX
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, or 1.0 mg of levothyroxine sodium per tablet

Dogs

Indication

For replacement therapy for diminished thyroid function in dogs.

Dosage

The initial dose is 0.1 mg/10 lb (0.01 mg/lb, 0.022 mg/kg) body weight twice daily.

Thyro-Tabs® Canine

SPL · SPL

Open original
FDA Structured Product Label

Thyro-Tabs® Canine

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Lloyd, Inc.
NADA
141-448
Status
RX
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, or 1.0 mg of levothyroxine sodium per tablet

Dogs

Indication
For replacement therapy for diminished thyroid function in dogs.
Dosage
Administer by mouth 0.1 mg/10 pounds of body weight (0.022 mg/kilogram) as a single dose every 24 hours or as a divided dose every 12 hours.
Limitations
For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FOI Summary oN 141-539 Approved January 15, 2021.pdf

FOI · FOI

Open original

UCM484490.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:07 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Tablet • Oral
Applications: NADA 141-539 • NADA 141-448
Documents: 2 (FOI: 2) • SPL: 2 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 22 • Cat 11 • View
Case summaries: 7 (showing 7) • View
openFDA reports are unverified and do not prove causation.
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Loss of appetite (1) Decreased percentage of reticulocytes (1) Decreased mean corpuscular volume (1) Decreased blood urea nitrogen (BUN) or creatinine (1) Death by euthanasia (1) Confusion (1) Complication of diabetes (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141448 NADA: 141539 NDC Package: 11695-6957-1 NDC Package: 11695-6957-2 NDC Package: 11695-6958-1 NDC Package: 11695-6958-2 NDC Package: 11695-6959-1 NDC Package: 11695-6959-2 NDC Package: 11695-6960-1 NDC Package: 11695-6960-2 NDC Package: 11695-6961-1 NDC Package: 11695-6961-2 NDC Package: 11695-6962-1 NDC Package: 11695-6962-2 NDC Package: 11695-6963-1 NDC Package: 11695-6963-2 NDC Package: 11695-6964-1 NDC Package: 11695-6964-2 NDC Package: 11695-6965-1 NDC Package: 11695-6965-2 NDC Package: 11695-7014-1 NDC Package: 11695-7014-2 NDC Package: 11789-048-10 NDC Package: 11789-048-20
Package NDC Product NDC Form / Route Status
11695-6957-1 11695 -
11695-6957-2 11695 -
11695-6958-1 11695 -
11695-6958-2 11695 -
11695-6959-1 11695 -
11695-6959-2 11695 -
11695-6960-1 11695 -
11695-6960-2 11695 -
11695-6961-1 11695 -
11695-6961-2 11695 -
11695-6962-1 11695 -
11695-6962-2 11695 -
11695-6963-1 11695 -
11695-6963-2 11695 -
11695-6964-1 11695 -
11695-6964-2 11695 -
11695-6965-1 11695 -
11695-6965-2 11695 -
11695-7014-1 11695 -
11695-7014-2 11695 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 11 Clinical 8 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Clinical, 2026-04-16)
  • contraindications: For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Clinical, 2026-04-15)
  • contraindications: For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Clinical, 2026-04-11)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • side_effects: Top reported reactions (openFDA): Overdose, Vomiting, Diarrhoea, Lethargy (see also Central nervous system depression in 'Neurological'), Panting, Lack of effi… (Clinical, 2026-04-11)
  • usage: For replacement therapy for diminished thyroid function in dogs. (Clinical, 2026-04-16)
  • usage: For replacement therapy for diminished thyroid function in dogs. (Clinical, 2026-04-15)
  • usage: For replacement therapy for diminished thyroid function in dogs. (Clinical, 2026-04-11)
  • contraindications: For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Official, 2026-04-22)
  • contraindications: For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Overdose, Vomiting, Diarrhoea, Lethargy (see also Central nervous system depression in 'Neurological'), Panting, Lack of effi… (Official, 2026-04-22)
  • side_effects: Top reported reactions (openFDA): Overdose, Vomiting, Diarrhoea, Lethargy (see also Central nervous system depression in 'Neurological'), Panting, Lack of effi… (Official, 2026-04-16)
  • side_effects: Top reported reactions (openFDA): Overdose, Vomiting, Diarrhoea, Lethargy (see also Central nervous system depression in 'Neurological'), Panting, Lack of effi… (Official, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Overdose, Vomiting, Diarrhoea, Lethargy (see also Central nervous system depression in 'Neurological'), Panting, Lack of effi… (Official, 2026-02-12)
  • usage: For replacement therapy for diminished thyroid function in dogs. (Official, 2026-04-22)
  • usage: Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. (Official, 2026-04-16)
  • usage: For replacement therapy for diminished thyroid function in dogs. (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-16 10:08 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-16 10:08 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-16 10:08 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-16 10:08 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-16 10:08 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-16 10:08 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-16 10:08 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-16 10:08 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-16 10:08 by curated_loader • Official FDA application reference for Senvelgo.
  • side_effects updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
ThyroKare™
RX
Levothyroxine sodium
Tablet • Oral
Label highlights
Official documents
Neogen Corp. NADA 141-539 Approved Feb 1, 2021
Thyro-Tabs® Canine
RX
Levothyroxine sodium
Tablet • Oral
Label highlights
Official documents
Lloyd, Inc. NADA 141-448 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, or 1.0 mg of levothyroxine sodium per tablet
Dogs
Indication

For replacement therapy for diminished thyroid function in dogs.

Dosage

The initial dose is 0.1 mg/10 lb (0.01 mg/lb, 0.022 mg/kg) body weight twice daily.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, or 1.0 mg of levothyroxine sodium per tablet
Dogs
Indication
For replacement therapy for diminished thyroid function in dogs.
Dosage
Administer by mouth 0.1 mg/10 pounds of body weight (0.022 mg/kilogram) as a single dose every 24 hours or as a divided dose every 12 hours.
Limitations
For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

For replacement therapy for diminished thyroid function in dogs.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Dog Decreased appetite (1) • Dog

Showing top 5 for Digestive.

Skin & allergy
Hair loss (1) • Dog

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Cat

Showing top 5 for Neurologic.

Other
Decreased urine concentration (1) • Dog Decreased percentage of reticulocytes (1) • Dog Decreased mean corpuscular volume (1) • Dog Decreased drinking (1) • Dog Decreased blood urea nitrogen (BUN) or creatinine (1) • Dog
Show more (23)
Death by euthanasia (1) • Dog Cough (1) • Dog Confusion (1) • Dog Complication of diabetes (1) • Dog Collapse of leg (1) • Dog Cold feeling of extremity (1) • Dog Circumstance or info capable of leading to medication error (1) • Cat Cataract (1) • Dog Bumping into walls (1) • Dog Bloody stool (1) • Dog Blindness (1) • Dog Bilirubinuria (1) • Dog Basophilia (1) • Dog Bacterial skin infection NOS (1) • Dog Aspiration pneumonia (1) • Dog Arthritis (1) • Dog Anaemia NOS (1) • Dog Allergic reaction (1) • Cat Alkaline urine (1) • Dog Agitation (1) • Cat Acidic urine (1) • Dog Accidental exposure (1) • Cat Abnormal cytology (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Retriever - Labrador, Female, 9 year, 47.446 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Unsteady walking (ataxia) • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-075417
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 9.00 Year
  • Weight: 47.446 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Unsteady walking (ataxia)
Outcomes: Recovered/Normal

Dog, Siberian Husky, Male, 11 year, 30.16 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Polyuria, Polydipsia, Skin discolouration NOS, Poor coat condition, Complication of diabetes… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074352
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.00 Year
  • Weight: 30.160 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Polyuria Polydipsia Skin discolouration NOS Poor coat condition Complication of diabetes Elevated thyroxine Elevated cholesterol Partial lack of efficacy Weight gain
Outcomes: Ongoing

Dog, Akita, Female, 6 year, 52.617 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Collapse of leg, Hind limb paralysis • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-071706
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 6.00 Year
  • Weight: 52.617 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
Collapse of leg Hind limb paralysis
Outcomes: Recovered/Normal

Dog, Maltese, Male, 12 year, 4.9 kilogram • Drug: MSK, Oral • Reactions: Loss of hearing • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-071474
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 12.00 Year
  • Weight: 4.900 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
Reactions Reported:
Loss of hearing
Outcomes: Ongoing

Dog, ['Terrier - Yorkshire', 'Terrier (unspecified)'], Female, 12 year, 5.321 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Diarrhea, Bloody stool • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-071832
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 12.00 Year
  • Weight: 5.321 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
Diarrhea Bloody stool
Outcomes: Recovered/Normal

Dog, Terrier - Yorkshire, Female, 13 year, 6.12 kilogram • Drug: MSK, Unknown • Reactions: Partial lack of efficacy, Hair loss, Erythema, Papule, Excoriation… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-072174
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 13.00 Year
  • Weight: 6.120 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Partial lack of efficacy Hair loss Erythema Papule Excoriation Skin scab Bacterial skin infection NOS Abnormal cytology
Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 13 year, 5.5 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Elevated creatine-kinase, Unsteady walking (ataxia), Stiffness limb, Unable to stand, Not eating… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-069207
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 13.00 Year
  • Weight: 5.500 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Elevated creatine-kinase Unsteady walking (ataxia) Stiffness limb Unable to stand Not eating Weight loss Tiredness (lethargy) Lying down Uncomfortable Abnormal cytology Intentional misuse
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.